At NYU Langone’s Center for Psychedelic Medicine, our scientists conduct and promote research across the translational spectrum in order to realize the clinical potential of these drugs, maximize their safety, unlock their mechanisms of action, and determine which patients are most likely to benefit from psychedelic treatments. Studies range from preclinical research to phase 3 clinical trials and include the assessment of psychedelics in the treatment of psychiatric disorders (e.g., substance use disorder, alcohol use disorder, depression, post-traumatic stress disorder, and distress associated with life-threatening illness such as cancer), as well as emerging medical indications. Learn more about our current and recent research studies below and read our publications.

Clinical Research

We are actively recruiting participants for the following clinical studies:

• Psilocybin-Assisted Therapy for Smoking Cessation
• Psilocybin-Assisted Therapy for Depression and Anxiety in Advanced Cancer
• A Phase 3 Study Psilocybin for the Treatment of Major Depressive Disorder
• RE104 Safety and Efficacy Study in Postpartum Depression
• Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use Disorder

Learn more about participating in a clinical study.

Recently Completed Clinical Trials

We’ve recently completed the following clinical trials:

• Cannabidiol (CBD) for Chronic Radicular Pain
• Cannabidiol (CBD) for Alcohol Use Disorder
• Psilocybin for the Treatment of Major Depressive Disorder
• Psilocybin-Assisted Therapy for Treatment of Alcohol Use Disorder